Literature DB >> 19538959

Antiretroviral protease inhibitors potentiate chloroquine antimalarial activity in malaria parasites by regulating intracellular glutathione metabolism.

Zhengxiang He1, Lili Chen, Jianlan You, Li Qin, Xiaoping Chen.   

Abstract

Antiretroviral protease inhibitors significantly potentiated the sensitivity of chloroquine-resistant malaria parasites to the antimalarial drug in vitro and in vivo. Ritonavir was found to be potent in potentiating CQ antimalarial activities in both -resistant and -sensitive lines. The mechanism by which the APIs modulate the CQ resistance in malaria parasites was further investigated. CQ-resistant parasites showed increased intracellular glutathione levels in comparison with the CQ-sensitive parasites. Treatment with APIs significantly reduced the levels of GSH and glutathione S-transferase activities in CQ-resistant parasites. Ritonavir also decreased glutathione reductase activities and glutathione peroxidase activities in CQ-resistant parasite line. Taken together, these results demonstrate that parasite GSH and GST may play an important role in CQ resistance and APIs are able to enhance the sensitivity of CQ-resistant malaria parasite to the drug by influencing the levels of GSH and the activities of the related enzymes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19538959     DOI: 10.1016/j.exppara.2009.06.008

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  14 in total

1.  Degrees of chloroquine resistance in Plasmodium - is the redox system involved?

Authors:  Adele M Lehane; Christopher A McDevitt; Kiaran Kirk; David A Fidock
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-12-01       Impact factor: 4.077

2.  Antimalarial effects of human immunodeficiency virus protease inhibitors in rhesus macaques.

Authors:  Youjia Li; Li Qin; Nanzheng Peng; Guangjie Liu; Siting Zhao; Zhengxiang He; Xiaoping Chen
Journal:  Antimicrob Agents Chemother       Date:  2011-04-12       Impact factor: 5.191

3.  Piperaquine and Lumefantrine resistance in Plasmodium berghei ANKA associated with increased expression of Ca2+/H+ antiporter and glutathione associated enzymes.

Authors:  Daniel Kiboi; Beatrice Irungu; Jennifer Orwa; Luna Kamau; Lynette Isabella Ochola-Oyier; Joseph Ngángá; Alexis Nzila
Journal:  Exp Parasitol       Date:  2014-10-18       Impact factor: 2.011

4.  Synergy of the antiretroviral protease inhibitor indinavir and chloroquine against malaria parasites in vitro and in vivo.

Authors:  Xiaofen Li; Zhengxiang He; Lili Chen; Yayong Li; Qinyan Li; Siting Zhao; Zhu Tao; Wen Hu; Li Qin; Xiaoping Chen
Journal:  Parasitol Res       Date:  2011-05-03       Impact factor: 2.289

5.  In vitro activity of antiretroviral drugs against Plasmodium falciparum.

Authors:  Christian Nsanzabana; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

6.  Saquinavir inhibits the malaria parasite's chloroquine resistance transporter.

Authors:  Rowena E Martin; Alice S Butterworth; Donald L Gardiner; Kiaran Kirk; James S McCarthy; Tina S Skinner-Adams
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

7.  The antiretroviral protease inhibitor ritonavir accelerates glutathione export from cultured primary astrocytes.

Authors:  Christian Arend; Maria Brandmann; Ralf Dringen
Journal:  Neurochem Res       Date:  2013-01-23       Impact factor: 3.996

8.  HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites.

Authors:  Yenisey Alfonso; Lianet Monzote
Journal:  Open Med Chem J       Date:  2011-03-09

9.  Drugs for malaria: something old, something new, something borrowed.

Authors:  Charlotte Hobbs; Patrick Duffy
Journal:  F1000 Biol Rep       Date:  2011-11-01

10.  HIV proteinase inhibitors target the Ddi1-like protein of Leishmania parasites.

Authors:  Rhian E White; David J Powell; Colin Berry
Journal:  FASEB J       Date:  2011-01-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.